Choreo LLC Has $260,000 Holdings in GSK plc (NYSE:GSK)

Choreo LLC lessened its holdings in shares of GSK plc (NYSE:GSKFree Report) by 18.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,069 shares of the pharmaceutical company’s stock after selling 1,380 shares during the quarter. Choreo LLC’s holdings in GSK were worth $260,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. PDS Planning Inc acquired a new position in GSK during the first quarter worth approximately $218,000. Argent Advisors Inc. increased its stake in shares of GSK by 8.7% during the first quarter. Argent Advisors Inc. now owns 25,630 shares of the pharmaceutical company’s stock worth $1,099,000 after purchasing an additional 2,041 shares during the period. Janney Montgomery Scott LLC increased its stake in shares of GSK by 10.5% during the first quarter. Janney Montgomery Scott LLC now owns 346,185 shares of the pharmaceutical company’s stock worth $14,841,000 after purchasing an additional 32,979 shares during the period. Mission Wealth Management LP bought a new position in shares of GSK during the first quarter worth approximately $272,000. Finally, Sequoia Financial Advisors LLC increased its stake in shares of GSK by 4.7% during the first quarter. Sequoia Financial Advisors LLC now owns 22,177 shares of the pharmaceutical company’s stock worth $951,000 after purchasing an additional 1,000 shares during the period. Institutional investors and hedge funds own 15.74% of the company’s stock.

Analysts Set New Price Targets

GSK has been the topic of a number of recent research reports. The Goldman Sachs Group assumed coverage on GSK in a research note on Thursday, May 30th. They set a “neutral” rating and a $47.00 target price on the stock. UBS Group downgraded GSK from a “buy” rating to a “neutral” rating in a report on Monday. Citigroup raised GSK to a “strong-buy” rating in a report on Monday, June 24th. Berenberg Bank raised GSK to a “strong-buy” rating in a report on Thursday, June 20th. Finally, Jefferies Financial Group raised their target price on GSK from $52.50 to $53.00 and gave the company a “buy” rating in a report on Tuesday, July 2nd. One investment analyst has rated the stock with a sell rating, three have given a hold rating, two have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, GSK has a consensus rating of “Moderate Buy” and a consensus target price of $50.00.

Get Our Latest Analysis on GSK

GSK Stock Down 0.3 %

Shares of GSK opened at $38.72 on Tuesday. GSK plc has a 52 week low of $33.67 and a 52 week high of $45.92. The stock has a market capitalization of $80.25 billion, a price-to-earnings ratio of 14.03, a PEG ratio of 1.18 and a beta of 0.64. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.58 and a current ratio of 0.87. The stock has a fifty day moving average of $42.20 and a 200-day moving average of $41.32.

GSK (NYSE:GSKGet Free Report) last announced its quarterly earnings results on Wednesday, May 1st. The pharmaceutical company reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $0.94 by $0.15. GSK had a return on equity of 51.54% and a net margin of 14.62%. The company had revenue of $9.34 billion during the quarter, compared to analysts’ expectations of $8.98 billion. As a group, sell-side analysts anticipate that GSK plc will post 4.1 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 11th. Investors of record on Friday, May 17th will be given a dividend of $0.3762 per share. This is a positive change from GSK’s previous quarterly dividend of $0.36. This represents a $1.50 annualized dividend and a yield of 3.89%. The ex-dividend date of this dividend is Thursday, May 16th. GSK’s dividend payout ratio (DPR) is currently 53.26%.

About GSK

(Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

Recommended Stories

Institutional Ownership by Quarter for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.